Zentalis Pharmaceuticals
(NASDAQ) ZNTL
Zentalis Pharmaceuticals Financials at a Glance
Market Cap
$151.79M
Revenue (TTM)
$0.00
Net Income (TTM)
$137.06M
EPS (TTM)
$-1.91
P/E Ratio
-1.12
Dividend
$0.00
Beta (Volatility)
1.76 (High)
Dividend
$0.00
Beta (Volatility)
1.76 (High)
Price
$2.34
Volume
15,901
Open
$2.27
Price
$2.34
Volume
15,901
Open
$2.27
Previous Close
$2.34
Daily Range
$2.27 - $2.39
52-Week Range
$1.01 - $3.95
Dividend
$0.00
Beta (Volatility)
1.76 (High)
Price
$2.34
Volume
15,901
Open
$2.27
Previous Close
$2.34
Daily Range
$2.27 - $2.39
52-Week Range
$1.01 - $3.95
ZNTL News
ZNTL: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Zentalis Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
106
CEO
Julia Marie Eastland, MBA
Website
www.zentalis.comHeadquarters
New York City, NY 10018, US
ZNTL Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-50%
Return on Capital
-61%
Return on Assets
-47%
Earnings Yield
-89.29%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$151.79M
Shares Outstanding
70.93M
Volume
15.90K
Short Interest
0.00%
Avg. Volume
1.30M
Financials (TTM)
Gross Profit
$739.00K
Operating Income
$146.25M
EBITDA
$145.51M
Operating Cash Flow
$125.25M
Capital Expenditure
$0.00
Free Cash Flow
$125.25M
Cash & ST Invst.
$245.89M
Total Debt
$39.58M
Zentalis Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
$157.00K
-100.6%
Gross Margin
0.00%
N/A
Market Cap
$151.79M
N/A
Market Cap/Employee
$914.41K
N/A
Employees
166
N/A
Net Income
$35.22M
+25.8%
EBITDA
$37.24M
+18.7%
Quarterly Fundamentals
Net Cash
$206.32M
-37.2%
Accounts Receivable
$1.93M
-61.4%
Inventory
$0.00
N/A
Long Term Debt
$35.70M
-9.8%
Short Term Debt
$3.87M
+26.1%
Return on Assets
-47.43%
N/A
Return on Invested Capital
-60.54%
N/A
Free Cash Flow
$30.94M
+22.1%
Operating Cash Flow
$30.94M
+22.1%